Acrolein is an electrophilic a,b-unsaturated aldehyde of industrial, pharmaceutic, and toxicologic importance to which we are exposed in environmental, occupational, and therapeutic situations. Acrolein is known to exert different biologic effects through reactions with cellular macromolecules such as DNA, certain proteins, or glutathione. In many situations (such as in tobacco smoke or other fumes), exposure to acrolein occurs concomitantly with other compounds such as aromatic amine chemicals. Interestingly, it has been shown that acrolein could impact the cellular metabolism of aromatic xenobiotics through an indirect mechanism based on the transcriptional induction of phase II xenobiotic-metabolizing enzymes. Here we report a novel mechanism by which acrolein acts on the metabolism of aromatic foreign chemicals. We provide molecular, kinetic, and cellular evidence that acrolein can react directly and irreversibly with arylamine N-acetyltransferases, a major family of xenobiotic-metabolizing enzymes involved in the metabolization of aromatic amine chemicals. Formation of an acrolein adduct with a catalytic cysteine residue in the active site is responsible for the impairment of aromatic amine acetylation by the enzyme. This biochemical process may represent an additional mechanism by which acrolein impacts the metabolism and fate of aromatic amine drugs and pollutants.
Introduction
Acrolein (ACR) is a three-carbon a,b-unsaturated aldehyde to which humans are widely exposed in environmental, occupational, and therapeutic situations. ACR is highly abundant in tobacco smoke, cooking, and automobile exhaust fumes (Kehrer and Biswal, 2000; Myers and Myers, 2009 ). In addition, ACR is used industrially as an herbicide and slimicide as well as a starting material for acrylate polymers and acrylic acid. Although ACR is an ubiquitous pollutant and major component of cigarette smoke, it is also generated endogenously by cellular metabolism and lipid peroxidation (Kehrer and Biswal, 2000; Myers and Myers, 2009) . Moreover, ACR is also a metabolite of the anticancer drug cyclophosphamide and is believed to be the main cause of its toxicity (Kehrer and Biswal, 2000) . ACR is the most reactive electrophile among a,b-unsaturated aldehydes. Its cellular toxicity relies mainly on its ability to deplete glutathione and to form DNA and protein adducts (Cai et al., 2009 ). Formation of ACR-protein covalent adducts is principally due to a Michael addition where the b-carbon of acrolein reacts with nucleophilic groups to form the 1,4 addition with the double bond (Cai et al., 2009; Martyniuk et al., 2011) .
Exposure to ACR generally occurs mainly in the context of chemical mixtures (e.g., as tobacco smoke) containing other potentially toxic compounds such as aromatic amine (AAs) chemicals (Feng et al., 2006; Myers and Myers, 2009) . AAs encompass several compounds with important pharmacologic (such as Sulfamide drugs) and industrial applications (such as in the manufacturing of drugs, pesticides, dyes, and rubbers). AAs are also byproducts of gasoline combustion and pyrolysis reactions. AAs represent one of the most important classes of occupational and/or environmental pollutants (Kim and Guengerich, 2005) , and these aromatic molecules account for 12% of the chemicals that are either known or strongly suspected to be human carcinogens (NTP, 2011) .
Human arylamine N-acetyltransferases (NAT1 and NAT2) are phase II xenobiotic-metabolizing enzymes (XME) that play a major role in the biotransformation of AA (Hein, 1988; Grant, 1993) . The interrelationship between variable NAT activities and the biologic effects of AA drugs and carcinogens has been known for years (Hein et al., 2000; Agundez, 2008) . Indeed, NATs catalyze the acetyl-CoA-dependent Nacetylation and/or O-acetylation of AAs and their N-hydroxylated metabolites (Sim et al., 2008) . NAT-dependent acetylation of AAs is a major biotransformation pathway that can have pharmacologic and toxicologic consequences (Hein, 1988; Butcher et al., 2008; RodriguesLima et al., 2008) .
Concomitant exposure to ACR and AAs occurs commonly (such as in cigarette smoke). It has been suggested that ACR could impact the cellular metabolism and hence the toxicologic fate of chemicals such as AAs, in particular through the transcriptional regulation of phase II XME (Tirumalai et al., 2002) . Herein, we provide molecular, kinetic, and cellular evidence that ACR reacts irreversibly with NAT1 enzyme through covalent adducts at the active site. This modification leads to irreversible inhibition of NAT1 and subsequent alteration of AA acetylation. This biochemical process may represent an additional mechanism by which ACR modifies the metabolism of AA drugs and carcinogens.
Materials and Methods
Materials. Acrolein (ACR), 2-aminofluorene (2-AF), p-aminosalicylic acid (PAS), p-nitrophenylacetate (PNPA), acetyl-coenzyme A (AcCoA), 1,4-dithiothreitol (DTT), biotin hydrazide, fluorescein-iodoacetamide, reduced glutathione (GSH), 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT), protease inhibitor cocktail, and nickel agarose resin were obtained from (A) Cells in six-well plates (90% confluence) were exposed to different concentrations of ACR for 30 minutes at 37°C. After ACR treatment, the cells were washed and grown in fresh culture medium in presence of 500 mM 2-AF. At given time points (2, 4, and 6 hours), the amount of acetylated 2-AF was quantitated in culture medium by HPLC. Error bars indicate the S.D. values (*P , 0.05). (B) NCIH-292 cells in six-well plates were exposed to different concentrations of ACR for 30 minutes. After washing, cell extracts were created (15 mg/mL protein concentration), and the residual NAT activity was assessed by HPLC using 2-AF as a substrate. Error bars indicate the S.D. values (*P , 0.05). (C) NCIH-292 in Petri dishes was exposed or not to 25 or 100 mM ACR for 30 minutes at 37°C. Endogenous NAT1 enzyme was immunoprecipitated from the cell extracts using anti-NAT1 antibodies. Bound enzyme was eluted and analyzed by Western blot using anti-NAT1 and anti-ACR adducts (lower panel). Equivalent amounts of NAT1 enzyme were present in the three different cell extracts used for immunoprecipitation, as shown by Western blot analysis using anti-NAT1 (upper panel).
Sigma-Aldrich (St. Louis, MO). The Bradford protein assay kit was supplied by Bio-Rad Laboratories (Hercules, CA). All other reagents were purchased from Euromedex (Bas Rhin, France) unless otherwise noted. Antibodies against ACR (rabbit polyclonal), biotin (rabbit polyclonal), and fluorescein (mouse monoclonal) were purchased from LifeSpan Biosciences (Seattle, WA), SigmaAldrich, and Roche Applied Science (Penzberg, Germany), respectively. Rabbit polyclonal anti-human NAT1 antibody was raised in the laboratory against a synthetic peptide corresponding to the last 16 residues of human NAT1.
Production and Purification of Recombinant Human NAT1. Escherichia coli BL21 (DE3) cells containing a pET28a-based plasmid were used to produce 6x-histidine-tagged human NAT1, as previously described elsewhere (Dairou et al., 2004) . Purified NAT1 was reduced by incubation with 10 mM DTT for 10 minutes at 4°C and dialyzed against Tris-HCl 25 mM, pH 7.5 (buffer A). Purity was assessed by SDS-PAGE, and protein concentrations were determined using the Bradford reagent following the manufacturer's instructions with bovine serum albumin as a standard.
Activity of Recombinant NAT1. NAT1 activity was detected in a total volume of 100 ml. Samples containing recombinant enzyme were first incubated with PAS (500 mM final concentration) in phosphate-buffered saline (PBS) at 37°C for 5 minutes. We added p-nitrophenylacetate (2 mM final concentration) to start the reaction, the samples were incubated for various periods (up to 30 minutes) at 37°C, and the absorbance was measured every 1 minute at 450 nm. All assays were performed in triplicate under initial reaction rate. Enzyme activity is expressed as the percentage of the control. In all reaction mixtures, the final concentration of NAT1 was 30 nM.
Reaction of Recombinant NAT1 with ACR. The effect of ACR on NAT1 activity was assessed by incubating the purified enzyme (3 mM final) with various concentrations of ACR in buffer A for 30 minutes at 37°C. Aliquots were then assayed for residual NAT1 activity.
Effects of Reducing Agents on ACR-Dependent Inhibition of Recombinant NAT1. We tested whether reducing agents (reduced glutathione, GSH, and dithiothreitol, DTT) could restore the activity of the NAT1 inhibited by ACR. Recombinant NAT1 (3 mM) was first preincubated with ACR (final concentration 25 mM) for 10 minutes at 37°C. Mixtures were then incubated with different concentrations of DTT or GSH (up to 10 mM final concentration) for 10 minutes at 37°C. Residual enzyme activities were then assessed. Control assays were performed in the conditions described earlier with GSH or DTT.
Effects of Acetyl-CoA and CoA on ACR-Dependent Inhibition of Recombinant NAT1. To analyze the involvement of the catalytic cysteine residue of human NAT1 in the ACR-dependent inhibition of NAT1, recombinant enzyme (3 mM) was preincubated with different concentrations of AcCoA or CoA in 25 mM Tris-HCl, pH 7.5, for 5 minutes at 37°C (final concentration of AcCoA or CoA ranged from 0-3 mM). Mixtures were then incubated with ACR (20 mM) for 10 minutes at 37°C and then assayed for NAT1 activity after dilution (100-fold) with Tris-HCl buffer.
Kinetic Analysis of ACR-Dependent NAT1 Inhibition. NAT1 (3 mM) was incubated with ACR (final concentration ranging from 5 to 20 mM) at 37°C. At various time intervals, the aliquots were removed and assayed for residual activity. Semilog plot of time courses for the inhibition of NAT1 by various concentrations of ACR and Kitz-Wilson replot were performed for the kinetic analysis of the data (Cornish-Bowden, 2001 ).
SDS-PAGE and Western Blot Analysis. Samples treated or nontreated with ACR were mixed with SDS sample buffer, boiled 5 minutes at 95°C, and separated by SDS-PAGE. For the Western blot analysis, the proteins were electrotransferred onto a nitrocellulose membrane. The membrane was blocked by incubation with Tris-buffered saline/Tween 20 (TBS) supplemented with 5% nonfat milk powder for 1 hour in TBS. Antibodies were added, and the Fig. 2 . Effect of ACR on purified recombinant human NAT1. (A) NAT1 (3 mM) was incubated with different concentrations of ACR (1 to 100 mM) at 37°C for 30 minutes, and the residual activity was measured. NAT1 exposed only to buffer was used as the control. Error bars indicate the S.D. values. (B) For dot-blot experiments, purified recombinant NAT1 (3 mM final) was exposed or not to ACR (final concentration of 25 mM) for 30 minutes at 37°C and was spotted on nitrocellulose sheets using a dot-blot Bio-Rad Laboratories apparatus. Detection of ACR-protein adducts was performed with specific anti-ACR adduct antibodies. To further detect ACR adducts on NAT1 enzyme, we performed labeling experiments with biotin-hydrazide, a compound that reacts with the carbonyl group of covalently bound ACR. To this end, the NAT1 samples were incubated with biotin-hydrazide (2 mM) for 2 hours at room temperature before dot-blotting and immunodetection using antibiotin antibodies. Fluorescein-iodoacetamide, a compound that reacts with reduced cysteines, was used to detect ACR-dependent modification of NAT1 cysteine residues. To this end, NAT1 samples were incubated with fluorescein-iodoacetamide (20 mM) for 30 minutes at room temperature before dot-blotting and immunodetection with antifluorescein antibodies. All membranes were stained with Ponceau S to ensure that equal amounts of NAT1 were dotted. (C) The effects of AcCoA and CoA on the ACR-dependent inhibition of NAT1 were observed by incubating NAT1 (3 mM) with ACR (20 mM) in presence of different concentrations of AcCoA or CoA for 30 minutes at 37°C before the NAT1 activity determination. The data are the mean of experiments performed in triplicate, where the NAT1 activity was determined in triplicate. Errors bars indicate S.D. values. *P , 0.05 versus ACR-inhibited NAT1. membranes were incubated overnight in TBS at 4°C. Amersham ECL was used for detection. Dot Blotting. Recombinant NAT1 (3 mM) was incubated with ACR (25 mM) for 30 minutes at 37°C. Treated and nontreated samples were mixed with TBS buffer (up to 200 ml) and were dotted on nitrocellulose sheets using a BioRad Laboratories dot-blot apparatus. The membrane was blocked by incubation with Tris-buffered saline/Tween 20 (TBS) supplemented with 5% nonfat milk powder for 1 hour in TBS. Antibodies against ACR-adducts were added (1: 1000), and the membranes were incubated overnight in TBS at 4°C. Amersham ECL was used for detection. Ponceau stains were performed to ensure that equal amounts of NAT1 were dotted on the membrane.
To detect the free carbonyl group of ACR-adducts, treated and untreated NAT1 aliquots were further incubated with 2 mM biotin-hydrazide (a reagent that covalently labels carbonyl groups) for 2 hours at room temperature before dot-blotting and detection with an antibiotin antibody.
To detect ACR-dependent modification of cysteines residues, treated and nontreated NAT1 aliquots were further incubated with 20 mM fluoresceinconjugated iodoacetamide (a reagent that covalently labels free reduced cysteine residues) for 30 minutes at room temperature before dot blotting and detection with an antifluorescein antibody.
Cell Culture. NCI-H292 human lung epithelial cells were obtained from the American Type Culture Collection (Manassas, VA). The cells were grown at 37°C as monolayers in six-well plates or in 100-mm Petri dish in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal calf serum. No significant toxicity (.85% cell survival) was found after exposure (30 minutes) to ACR (up to 100 mM).
Detection of ACR-Adducted NAT1 in Cells. Cells in 10-cm Petri dishes were exposed to 25 or 100 mM ACR for 30 minutes at 37°C. After they were washing with PBS buffer, the cells were scraped in 500 ml of PBS containing 0.1% Triton X-100 and protease inhibitors before sonication and centrifugation at 17,000g for 15 minutes at 4°C. The supernatant was saved and used for immunoprecipitation of endogenous NAT1. To this end, equal amounts of the cell extracts (1.3 mg protein) were incubated with anti-NAT1 antibodies bound to protein A agarose beads overnight at 4°C. After several washes with PBS containing 0.1% Triton X-100, the immunoprecipitated NAT1 was eluted with SDS sample buffer (nonreducing). The eluted proteins were analyzed by Western blot with specific antibodies against ACR adducts.
Cellular NAT Activity Assay. NAT activity was measured in cell extracts using reverse-phase high-pressure liquid chromatography (HPLC) as described previously elsewhere (Grant et al., 1991) . Samples (50 ml) were first incubated with AA substrate (1 mM final) in assay buffer (25 mM Tris-HCl, pH 7.5) at 37°C for 5 minutes. AcCoA (1 mM final) was added, and the samples (100 ml final volume) were incubated at 37°C for various periods of time (up to 30 minutes). The reaction was quenched by adding 100 ml of ice-cold acetic acid (15% w/v), and the proteins were recovered by centrifugation for 5 minutes at 12,000g. We injected 20 ml of the supernatant into the C18 reverse-phase HPLC column. All assays were performed in triplicate under initial reaction rate conditions. Acetylation of 2-AF by Intact Lung Epithelial Cells in Culture. Acetylation of 2-AF by endogenous NAT in intact lung epithelial cells was measured by reverse-phase HPLC as described previously elsewhere (Wu et al., 2000) . Briefly, after exposure to ACR (up to 100 mM), the monolayers (six-well plates, 10 cm 2 per well, ;100 mg total protein) were washed with PBS and grown in the presence of 500 mM 2-AF in Dulbecco's modified Eagle's medium (DMEM) culture in a 37°C incubator. At different time points (3, 4, 5, and 6 hours), aliquots (100 ml) of culture medium were collected and added to 100 ml of ice-cold aqueous acetic acid (15% w/v). Samples were then centrifuged, and the amount of acetylated 2-AF was quantitated by HPLC analysis. Controls were examined in the same conditions with the cell monolayer not exposed to ACR. The appearance of N-acetylated AA in the culture medium was found to be linear with time.
Results and Discussion
Exposure to ACR occurs mainly through inhalation of smoke and fumes, where ACR concentrations can reach high levels. For instance, it has been shown that one cigarette bubbled through 10 ml of an aqueous buffer can generate ACR concentrations up to 500 mM (Lambert et al., 2005) . In the respiratory tract fluid of smokers, ACR was estimated to reach concentrations close to 100 mM (Jia et al., . Most of the adverse effects of ACR on humans are likely due to direct interaction with the lung epithelial cells, leading to the alteration of key cellular functions (Myers and Myers, 2009; Spiess et al., 2011) . These cells are known to express xenobiotic-metabolizing enzymes (such as NAT1) that are involved in the biotransformation of inhaled chemicals (Zhang et al., 2006; Dairou et al., 2009 ).
We first tested the effect of ACR exposure on the cellular acetylation of AA chemicals. To this end, we exposed human lung epithelial cell (NCI-H292) monolayers to different concentrations of ACR and measured the amount of acetylated 2-AF (a well-known AA that is specifically acetylated by NAT enzymes) in culture medium by HPLC. Brief exposure (30 minutes) of epithelial cells to ACR (up to 100 mM) led to a dose-dependent decrease in the amount of acetylated 2-AF in the culture medium (Fig. 1A) . Accordingly, enzyme assays with the extracts of the cells that had been exposed or not to ACR showed that cellular NAT1 is inhibited by ACR (with 80% inhibition of the enzyme activity at 100 mM ACR (Fig. 1B) .
ACR has a strong electrophilic character and forms covalent adducts with biologic molecules such as proteins, DNA, or GSH (Cai et al., 2009 ). Immunoprecipitation and Western-blotting experiments using specific antibodies against human NAT1 enzyme and ACRprotein adducts (Luo et al., 2007) have indicated that exposure of epithelial cells to ACR leads to the formation of ACR adducts on cellular NAT1 enzyme (Fig. 1C) . Taken together these data show that in lung epithelial cells ACR reacts with NAT1 through covalent protein adducts and impairs the NAT-dependent biotransformation of AA chemicals.
Further mechanistic and kinetics studies were performed to better understand the molecular basis for the effects of ACR on the enzymatic acetylation of AA chemicals. To this end, recombinant NAT1 enzyme (0.5 mM final concentration) was incubated with various concentrations of ACR (0-100 mM final concentration), and residual NAT1 activity was measured by following the AcCoA-dependent acetylation of PAS. Fig. 2A shows that NAT1 activity was significantly inhibited by ACR in a dose-dependent manner ( Fig. 2A) .
As observed for cellular NAT1, the recombinant enzyme was inhibited by biologically achievable concentrations of ACR (,100 mM) with an IC 50 value of 8 mM ( Fig. 2A) . The lack of reactivation of the enzyme by dilution with assay buffer or by dialysis (unpublished data) indicated that the ACR-dependent inhibition of NAT1 activity was irreversible. In addition, we found that NAT1 activity could not be recovered by high concentrations of reducing agents such as DTT or GSH (unpublished data) . This data suggested that ACR-dependent inhibition of recombinant NAT1 could be due to the formation of covalent adducts as observed when lung epithelial cells were exposed to ACR (Fig. 1) . Dot-blot experiments using recombinant NAT1 inhibited by ACR (25 mM final concentration) confirmed the formation of covalent ACR-enzyme adducts, which were readily detected by a specific antibody against ACR adducts (Fig. 2B) . To confirm the presence of these adducts on NAT1, we used biotin-hydrazide, a reagent that reacts specifically with the free aldehyde carbonyl group of covalently bound ACR (Spiess et al., 2011) . As shown in Fig. 2B , biotinhydrazide was found to react with NAT1 enzyme exposed to ACR, thus confirming the presence of ACR adducts on NAT1.
ACR, through its a,b-unsaturated moiety, is known to react covalently with cysteine residues to form covalent adducts (Seiner et al., 2007) . We used fluorescein-conjugated iodoacetamide (which reacts only with reduced cysteines) to detect the covalent modification of NAT1 cysteines by ACR. As shown in Fig. 2B , exposure to ACR decreased the labeling of NAT1 by fluorescein-iodoacetamide, thus demonstrating that ACR reacts with NAT1 cysteine residues.
Interestingly, the acetyltransferase activity of NAT1 relies on a cysteine residue present in the active site of the enzyme. This catalytic cysteine can be specifically acetylated by AcCoA (the physiologic acetyl donor) to form a covalent acetyl-enzyme intermediate. AcCoAprotection approaches take advantage of this property and have been used to identify whether the inhibition of NAT enzymes by chemicals involves reactions with the active site cysteine (Liu et al., 2008; Ragunathan et al., 2008) . As shown in Fig. 2C , AcCoA provided significant protection (80% 6 5% with 500 mM AcCoA). CoA, a product resulting from the hydrolysis of AcCoA that does not form an acetyl enzyme intermediate, provided no protection.
These data support that inhibition of NAT1-dependent acetylation is due to irreversible adduction at the active site cysteine of the enzyme. Similar results have been recently reported for other families of enzymes such as human protein tyrosine phosphatase 1B, protein disulfide isomerase, and glyceraldehyde 3-phosphate dehydrogenase, which are irreversibly inhibited by ACR through covalent Michael adducts with their catalytic cysteine residue (Carbone et al., 2005; Seiner et al., 2007; Martyniuk et al., 2011; Nakamura et al., 2013) . In aqueous solution, thiols react with ACR through conjugate addition to the double bond of the a,b-unsaturated aldehyde (thus forming a Michael adduct) rather than by addition to the aldehyde moiety (Seiner et al., 2007) . Consistent with this, analysis of a series of structurally related aldehydes indicate that the double bond found in 
